Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0453 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0453 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0453 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0453 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0453 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0453 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0453 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0453 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0453 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.028 | 0.2407 | 0.2407 |
Chlamydia trachomatis | sulfite reductase | 0.028 | 0.2407 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0453 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0453 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0453 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0453 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0453 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0402 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0453 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0402 | 0.7743 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0453 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0453 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0228 | 0.0151 | 0.0151 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0453 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0453 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0453 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0225 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0453 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0225 | 0 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0453 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Change (functional) | = -4 % | Percent change in nonimmune L3 inflammatory leisions in rat adjuvant-induced arthritis at 50 mg/kg | ChEMBL. | 4032421 |
Change (functional) | = -3 % | Percent change in nonimmune L16 inflammatory leisions in rat adjuvant-induced arthritis at 50 mg/kg | ChEMBL. | 4032421 |
Change (functional) | = -1 % | Percent change in immune R16 inflammatory leisions in rat adjuvant-induced arthritis at 50 mg/kg | ChEMBL. | 4032421 |
Change (functional) | = 15 % | Immunoregulatory activity against mouse contact sensitivity was evaluated as percent change | ChEMBL. | 4032421 |
Change (functional) | = 15 % | Immunoregulatory activity against mouse contact sensitivity was evaluated as percent change | ChEMBL. | 4032421 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.